» Articles » PMID: 16376306

Inhibition of RNAse A Family Enzymes Prevents Degradation and Loss of Silencing Activity of SiRNAs in Serum

Overview
Date 2005 Dec 27
PMID 16376306
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Small interfering RNAs (siRNA), RNA duplexes of approximately 21 nucleotides, offer a promising approach to specifically degrade RNAs in target cells by a process termed RNA interference. Insufficient in vivo-stability is a major problem of a systemic application of siRNAs in humans. The present study demonstrated that RNAse A-like RNAses degraded siRNAs in serum. The susceptibility of siRNAs towards degradation in serum was strongly enhanced by local clustering of A/Us within the siRNA sequence, i.e. regions showing low thermal stability, most notably at the ends of the molecule, and by 3'-overhanging bases. Importantly, inhibition of RNAse A family enzymes prevented the degradation and loss of silencing activity of siRNAs in serum. Furthermore, the degradation of siRNAs was considerably faster in human than in mouse serum, suggesting that the degradation of siRNAs by RNAse A family enzymes might be a more challenging problem in a future therapeutic application of siRNAs in humans than in mouse models. Together, the present study indicates that siRNAs are degraded by RNAse A family enzymes in serum and that the kinetics of their degradation in serum depends on their sequence. These findings might be of great importance for a possible future human therapeutic application of siRNAs.

Citing Articles

Single-Molecular Dissection of Liquid-Liquid Phase Transitions.

Pokhrel P, Jonchhe S, Pan W, Mao H J Am Chem Soc. 2023; 145(31):17143-17150.

PMID: 37494702 PMC: 10528544. DOI: 10.1021/jacs.3c03812.


A Combination Therapy Using Electrical Stimulation and Adaptive, Conductive Hydrogels Loaded with Self-Assembled Nanogels Incorporating Short Interfering RNA Promotes the Repair of Diabetic Chronic Wounds.

Lei H, Fan D Adv Sci (Weinh). 2022; 9(30):e2201425.

PMID: 36064844 PMC: 9596839. DOI: 10.1002/advs.202201425.


Keeping up with the COVID's-Could siRNA-based antivirals be a part of the answer?.

Forgham H, Kakinen A, Qiao R, Davis T Exploration (Beijing). 2022; :20220012.

PMID: 35941991 PMC: 9349879. DOI: 10.1002/EXP.20220012.


Multifunctional nanoparticles co-loaded with Adriamycin and MDR-targeting siRNAs for treatment of chemotherapy-resistant esophageal cancer.

Zhang X, Wang M, Feng J, Qin B, Zhang C, Zhu C J Nanobiotechnology. 2022; 20(1):166.

PMID: 35346194 PMC: 8962182. DOI: 10.1186/s12951-022-01377-x.


Dual pH-Responsive and Tumor-Targeted Nanoparticle-Mediated Anti-Angiogenesis siRNA Delivery for Tumor Treatment.

Zhang X, Qin B, Wang M, Feng J, Zhang C, Zhu C Int J Nanomedicine. 2022; 17:953-967.

PMID: 35280336 PMC: 8906879. DOI: 10.2147/IJN.S340926.